Journal article
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
Abstract
Rivaroxaban exposure and patient characteristics may affect the rivaroxaban benefit–risk balance. This study aimed to quantify associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation (NVAF), using data from the phase 3 ROCKET AF trial (NCT00403767). In ROCKET AF, 14,264 patients with NVAF were randomized to rivaroxaban (20 mg once …
Authors
Zhang L; Yan X; Fox KAA; Willmann S; Nandy P; Berkowitz SD; Hermanowski-Vosatka A; Weitz JI; Solms A; Schmidt S
Journal
Journal of Thrombosis and Thrombolysis, Vol. 50, No. 1, pp. 20–29
Publisher
Springer Nature
Publication Date
July 2020
DOI
10.1007/s11239-020-02077-9
ISSN
0929-5305